AstraZeneca (AZN) Chief Executive Sir Pascal Soriot has spoken privately on a number of occasions of his preference to move the company's stock market listing to the US, The Times reported Tuesday, citing multiple sources.

The CEO has also discussed moving the company's domicile, according to the report, which cited a source familiar with his thinking.

The drugmaker already trades in the US through American depositary receipts.

AstraZeneca did not immediately reply to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 71.53, Change: +1.65, Percent Change: +2.36